PRTA
Prothena Corporation plc (PRTA)
Healthcare • NASDAQ • $10.73+1.90%
- Symbol
- PRTA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $10.73
- Daily Change
- +1.90%
- Market Cap
- $561.75M
- Trailing P/E
- N/A
- Forward P/E
- -10.32
- 52W High
- $11.80
- 52W Low
- $4.32
- Analyst Target
- $21.40
- Dividend Yield
- N/A
- Beta
- -0.23
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinica…
Company websiteResearch PRTA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.